AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation...
Pharmaceutical
Correction to Company Announcement No. 1 of January 3, 2023
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with...
Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a...
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational...
Dyadic Announces Sale of Equity Interest in Alphazyme
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology...
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University...
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry...
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation proteome analysis platform to advance...
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
Conference to take place Feb. 6-9 in New YorkSIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq:...
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
-Results demonstrate sotigalimab’s ability to turn immunologically “cold” tumors “hot” to increase anti-tumor immune responses for increased therapeutic effect in...
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study...
Cool & homogeneous: Single Use Support introduces product innovation
RoSS.PADL Homogenizing Solution RoSS.PADL is a platform to standardize cooling of your single-use bag whilst gently massaging it to ensure...
Sunshine Biopharma Announces Share Repurchase Program
MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies...